Company attributes
Other attributes
Mersana Therapeutics is a publicly traded, clinical-stage biopharmaceutical company based in Cambridge, Massachusetts that was founded in 2001 by David R. Emaleh. Using its proprietary ADC platform, the company develops highly targeted drugs with increased tolerability and expanded opportunities to deliver clinical benefits to cancer patients.
Mersana's lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2B-expressing tumors. It entered clinical development in December 2017 and is in Phase 1 clinical trials in the dose escalation phase, as of January 2019.
Another product candidate's clinical development, XMR-1522, a Dolaflexin ADC targeting HEr2-expressing tumors, was discontinued in January 2019 following strategic evaluation of the program.
In January 2019, Mersana entered into a license agreement with Synnafix, a Dutch biotechnology company, to obtain access to Synaffix's GlycoConnect ADC technology. GlycoConnect is a platform technology utilizing proprietary enzymes and metal-free click conjugation to stably attach payloads specifically to the native glycan of any antibody, a privileged site for ADC applications.
On November 8, 2005 Mersana Therapeutics completed a venture capital round with 421 million in funding from ProQuest Investments (lead investor), F-Prime Capital Partners (lead Investor), Rho Capital Partners, PureTech Health, Lansing Brown Investments, Eight Roads Ventures, Cape Family Fund, and 180 degree Capital.
On April 8, 2014 Mersana Therapeutics completed their series A funding round with $14.5 million in funding from New Enterprise Associates and F-Prime Capital Partners.
On March 2, 2015 Mersana Therapeutics completed their series B funding round with $35 million in funding from New Enterprise Associates (lead investor), Rock Springs Capital, Pfizer Venture Investments, F-Prime Capital Partners, and Elliott Sigal.
